cigna glp-1 program Wins First Cir. Bias Case Over Weight-Loss Drug Coverage Cigna dropping GLP-1 obesity drug

If youre interested in learning more about Ipamorelin, its effects, or how it can fit into your wellness plan, please reach out to our team

and for those tesamorelin-treated patients completing the 26-week treatment period that were re-randomized to tesamorelin (T-T group) or re-randomized to placebo, 36.6% and 32.0%, respectively, had impaired glucose tolerance, while 2.0% re-randomized to tesamorelin and 6.0% re-randomized to placebo had diet-controlled diabetes mellitus

The effects are more gradual and less intense than what youd expect from pharmaceutical options, but thats part of the appeal for many people

doi: 10.1016/j.intimp.2020.106328 236 WangXGongSPuDHuNWangYFanPet al